Geneva Illinois

Geneva History Center , Geneva. What Was It Like?. . .Hiking Through Your Home Town ... [Read More]

Illinois Attorney General - Antitrusts Settlements
Hytrin, which is used in the treatment of hypertension and enlarged prostate, is manufactured by Abbott Laboratories, and the generic version (called "terazosin") is produced by Geneva Pharmaceuticals. According to a federal lawsuit, Abbott wrongfully paid Geneva to delay introduction of its generic version of Hytrin and took other steps to delay competition from lower-priced generic versions of its product. This illegal activity harmed consumers. ...

Under the settlement agreement, which is still subject to final court approval, Abbott and Geneva would provide $28.7 million for consumers and third-party payers in Illinois and 17 other states. The most direct way for consumers to obtain claims forms is through the settlement website, http://www.terazosinlitigation.com . Claims forms must be mailed to the settlement administrator no later than July 15, 2005. ... [Read More]

Union-Pacific West Line Extension
In April 1997, Metra initiated a Major Investment Study (MIS) for the Central Kane Corridor (CKC). The purpose of the MIS was to analyze the ability and cost effectiveness of various alternative investment strategies to serve the growing need for travel from the CKC to the Chicago central business district. The MIS was completed in August 1998. Based on the results of the MIS, Metra selected Rail Alternative R1 as the Locally Preferred Alternative (LPA) that would implement an extension of commuter rail service from Geneva to Elburn, Illinois. The LPA was included in the Chicago Area Transportation Study's (local Metropolitan Planning Organization) 2020 Long-Range Transportation Plan and Transportation Improvement Program in November 1997. In December 1998, FTA approved Metra's request to initiate the preliminary engineering/environmental review process on the UPW extension project. Metra completed an Environmental Assessment (EA) for the project in June 2000. FTA issued a Finding of N ... [Read More]

Abbott Laboratories, et al. - Complaint
23. As the first generic company to submit a Paragraph IV Certification for generic terazosin HCL, Geneva was entitled to the 180-day Exclusivity Period pursuant to the Hatch-Waxman Act, as currently interpreted. Unless and until Geneva's 180-day Exclusivity Period had been triggered and had expired, or Geneva relinquished its entitlement to this period of exclusivity, only Geneva would be approved by the FDA to market a generic terazosin HCL product. ...

38. By prohibiting Geneva from transferring, assigning, or giving up its right to a 180-day Exclusivity Period until the final resolution of the patent infringement litigation involving Geneva's terazosin HCL tablets product, the Agreement had the purpose and effect of preventing Geneva from relinquishing its eligibility for a 180-day Exclusivity Period under the Hatch-Waxman Act. As of February 1999, at least one other generic manufacturer had satisfied the FDA's requirements for approval and was barred from entering the market because Geneva's 180-day Exclusivity Period had not begun to run. ... [Read More]

Geneva Swedish Days
Held the last week in June, Geneva Swedish Days celebrates the heritage of Swedish immigrants who settled in the area. A Swedish smorgasbord and rosemaling show are hosted by the local church community, and traditional old world costumes are worn. Arts and crafts exhibits, a music competition, a carnival, a Kids' Day, a flea market, nightly entertainment on the Courthouse lawn, and a parade are part of the festivities. Merchants host special sales and in-store events, as well as sponsoring main festival programs and donating in-kind services. Twenty-one food stands throughout the downtown area tempt visitors with Swedish and American menus. The 1999 festival was the 50th anniversary of Swedish Days. ... [Read More]

Illinois Association of Museums
Planned special events are going to be very exciting. We will open Wednesday evening with a reception in the new award-winning permanent exhibit at the Geneva History Center. Thursday evening’s progressive dinner might include hors doeuvres in a nineteenth century mansion or on a farm, dinner at a currently-undisclosed location, and dessert in a Wrightian villa or around a campfire. The Tri-Cities certainly offers variety! The Awards Luncheon on Friday will be in the historic Rainbow Room of the Hotel Baker in St. Charles. The Friday afternoon sessions will also be held at the Baker, listed on the National Register of Historic Places for its architecture and historic significance.This year’s keynote speaker will be Ida Tomlin, COO of The New DetroitScience Center and Association of Midwest Museums board member. ... [Read More]

Rep. J. Dennis Hastert, 14th District of Illinois
Amboy – Annawan – Ashton – Atkinson – Aurora – Bartlett* – Batavia – Big Rock – Binghampton – Bristol – Burlington – Cambridge – Carpentersville – Central – Compton – Cortland – Deer Grove – DeKalb – Dixon – Dundee – East Dundee - Elburn – Eldena – Elgin – Elva – Fox – Franklin Grove – Gap Grove – Geneseo – Geneva – Gilberts – Hampshire – Harmon – Helmar – Hinckley – Hooppole – Huntley – Kaneville – Kewanee - LaFox – Lee – Lee Center – Lily Lake – Lisbon - Little Rock – Maple Park – Maytown – McGirr – Millbrook – Millington – Minooka – Montgomery – Mooseheart – Nachusa – Nelson – Newark – New Bedford – Normandy – North Aurora – Orion – Osco – ... [Read More]

Geneva Pharmaceuticals, Inc. and Abbott Laboratories - Analysis
The complaint challenges an agreement whereby Abbott, following the FDA approval of Geneva's generic terazosin HCL capsule product, paid Geneva not to enter the market during their ongoing patent litigation over the tablet product. According to the complaint, on the day it was granted approval to market its generic terazosin HCL capsules, Geneva contacted Abbott and announced that it would launch its generic terazosin HCL capsules unless it was paid by Abbott not to enter. Two days later, on April 1, 1998, Abbott and Geneva entered into an agreement, pursuant to which Geneva agreed not to enter the market with any generic terazosin HCL capsule or tablet product until the earlier of: (1) the final resolution of the patent infringement litigation involving Geneva's terazosin HCL tablets product, including review through the Supreme Court; or (2) entry of another generic terazosin HCL product. ... [Read More]